Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01195636 · ClinicalTrials.gov registry record · Phase 2
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
A Phase 2 study, sponsored by Xenon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01195636 is a Phase 2 study that has completed, run by Xenon Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT01195636, a Phase 2 study, has completed, sponsored by Xenon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia
Interventions
- DRUG Placebo
- DRUG XPF-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01195636
The ClinicalTrials.gov registry entry for NCT01195636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xenon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01195636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01195636 about?
NCT01195636 is a clinical study titled "A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)". The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia
What is the current status of trial NCT01195636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2010-08. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01195636?
The interventions under investigation include: Placebo (DRUG), XPF-002 (DRUG).
Who is sponsoring clinical trial NCT01195636?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.